8-K: Vaccinex to Voluntarily Delist from Nasdaq Amid Continued Listing Challenges

Vaccinex, Inc. has announced its intention to delist its common stock from the Nasdaq Stock Market following a suspension of trading and a determination by the Nasdaq Hearings Panel.

Summary

• Vaccinex, Inc. has notified Nasdaq of its decision to delist its common stock.
• Trading of Vaccinex's common stock on Nasdaq has been suspended since December 18, 2024.
• The company intends to file a Form 25 with the SEC on or about March 17, 2025, to officially remove its stock from the Nasdaq listing.
• The decision to delist follows a notice from the Nasdaq Hearings Panel on December 16, 2024, regarding the delisting of the company's securities.
• Vaccinex plans to focus on the development of its lead product, pepinemab, for treating Alzheimer's disease and cancer.
• The company intends to pursue partnerships, grants, and other financing avenues to support pepinemab's development.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the delisting from Nasdaq, which can impact investor confidence. However, the company's focus on developing pepinemab and seeking alternative funding sources provides a glimmer of hope.

Positives

• Vaccinex is focusing on the development of pepinemab, its lead drug candidate, for Alzheimer's disease and cancer.
• The company intends to pursue partnerships, grants, and other financing avenues to support pepinemab's development.

Negatives

• Vaccinex's common stock has been suspended from trading on Nasdaq since December 18, 2024.
• The company received a notice from the Nasdaq Hearings Panel regarding the delisting of its securities.

Risks

• The company's ability to secure partnerships, grants, and other financing avenues to support the development of pepinemab is uncertain.
• The development of pepinemab may face challenges and setbacks.

Future Outlook

Vaccinex plans to focus on the development of pepinemab for treating Alzheimer's disease and cancer through partnerships, grants, and other financing avenues.

Management Comments

• Vaccinex plans to continue to focus on development of its lead product, pepinemab, to treat Alzheimer's disease and cancer through partnerships, grants and other financing avenues.

Industry Context

Delisting from a major exchange like Nasdaq can impact a company's visibility and access to capital, potentially affecting its ability to fund research and development. Vaccinex's focus on pepinemab, a drug targeting neurodegenerative diseases and cancer, aligns with growing interest in these therapeutic areas within the biotechnology industry.

Comparison to Industry Standards

• Many biotechnology companies face challenges in maintaining Nasdaq listing compliance, especially during clinical development phases.
• Companies like Cassava Sciences and Anavex Life Sciences are also focused on Alzheimer's disease treatments, but their clinical and financial situations differ from Vaccinex.
• The decision to delist and pursue alternative funding strategies is not uncommon for companies facing financial constraints or regulatory hurdles.

Stakeholder Impact

• Shareholders may experience a decrease in the value and liquidity of their shares.
• Employees may face uncertainty regarding the company's future.
• The company's ability to develop and commercialize pepinemab may be affected.

Next Steps

• Vaccinex intends to file a Form 25 with the SEC on or about March 17, 2025.
• The company will focus on developing pepinemab through partnerships, grants, and other financing avenues.

Key Dates